Patent ID: 11857604
Assignee: NH THERAGUIX
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  B | IPC A  B

Claim 8:
9. The nanovector according to claim 8, wherein said anti-cancer substance is chosen from the following substances: actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabin, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, teniposide, tioguanine, topotecan, valrubicin, vemurafenib, vinblastine, vincristine, vindesine, lenalidomide, ibrutinib, abiraterone, erlotinib, everolimus, nilotinib, sunitinib, sorafenib, goserelin, nedaplatin, laboplatin, TATE peptide and heptaplatin, or a mixture thereof.